Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Inclusion Criteria

• •1. Ability to understand and willingness to sign a written informed consent document.
• •2. Aged at least 18 years old.
• •3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV).
• •4. Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .
• •5. At least one measurable lesion as defined by RECIST V1.1.
• •6. ECOG performance status 0 to 1.